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Adenoviruses use the virus-encoded virus-associated RNA (VAI RNA) as a defense against cellular antiviral
response by blocking the activation of the interferon-induced, double-stranded RNA-activated protein kinase
PKR. The structure of VAI RNA consists of two long, imperfectly base-paired duplex regions connected by a
complex short stem-loop at the center, referred to as the central domain. By using a series of adenovirus
mutants with linker-scan mutations in the VAI RNA gene, we recently showed that the critical elements
required for function in the VAI RNA molecule are in the central domain and that these same elements of the
central domain are also involved in binding to PKR. In virus-infected cells, VAI RNA interacts with latent
kinase, which is bound to ribosomes; this interaction takes place in a complex milieu. To more fully understand
the relationship between structure and function and to determine whether the in vivo phenotype of these
mutants can be reproduced in vitro, we have now analyzed these mutant VAI alleles for their ability to block
the activation of a partially purified PKR from HeLa cells. We have also derived the structure of these mutants
experimentally and correlated the structure with function. Without exception, when the structure of the short
stem-loop of the central domain was perturbed, the mutants failed to inhibit PKR. Structural disruptions
elsewhere in the central domain or in the long duplex regions of the molecule were not deleterious for in vitro
function. Thus, these results support our previous findings and underscore the importance of the elements
present in the central domain of the VAI RNA for its function. Our results also suggest that the interaction
between PKR and VAI RNA involves a precise secondary (and tertiary) structure in the central domain. It has
been suggested that VAI RNA does not activate PKR in virus-infected cells because of mismatches in the
imperfectly base-paired long duplex regions. We constructed mutant VAI genes in which the imperfectly
base-paired duplex regions were converted to perfectly base-paired regions and assayed in vitro for the
activation of PKR. As with the wild-type VAI RNA, these mutants failed to activate PKR in vitro, while they
were able to block the activation of PKR better than did the wild type. These results suggest that the failure
of VAI RNA to activate PKR is not the result of mismatches in the long duplex regions. Thus, the role of the
long duplex regions of VAI RNA is probably to hold the nucleotide sequences of the central domain in a
conformation optimal for function.
One way that cells defend against virus infection is by
activation of the interferon-induced, double-stranded RNA
(dsRNA)-activated protein kinase designated PKR (also
known as p68 kinase, eIF-2 alpha kinase, and dsRNA-activated
inhibitor), which, when activated, phosphorylates the alpha
subunit of the translation initiation factor eIF-2. The phos-
phorylated eIF-2 does not recycle and is sequestered in the
cell, leading to cessation of protein synthesis (reviewed in
references 19, 32, and 47). Viruses have evolved various
strategies to counteract this cellular antiviral response. The
strategy most extensively studied is that used by adenoviruses.
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They encode two RNA polymerase III-directed small RNAs,
designated virus-associated RNAs I and II (VAI and VAII
RNAs), that accumulate to high levels at late stages of
infection. In virus infections, VAI RNA is obligatory for
efficient translation of viral and cellular mRNAs at late times
(51, 56). It binds to and blocks the activation of PKR produced
by the cell, thereby enabling protein synthesis to proceed at
normal levels (1, 23, 26, 41, 49, 52; reviewed in references
33, 50, and 55). The structure of VAI RNA consists of two
long, imperfectly base-paired stems of 20 to 22 bp joined at
the center by a domain that is structurally complex and
that contains two loops and a short stem-loop (12, 38). This
domain is referred to as the central domain. Although ini-
tially it was thought that the long duplex regions might be
important in blocking the activation of the PKR, recent
mutational analysis showed that it is the central domain that is
critical for function (12, 38). These results are consistent with
VAI RNA-PKR interaction studies in vivo. The VAI mutants
with mutations that alter the integrity of the central domain did
not bind to PKR in vivo, whereas mutants with mutations that
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disrupt other regions of the molecule bound to PKR efficiently
(15).
The cellular target of VAI RNA, PKR, is a ribosome-bound
enzyme which is present in a latent state. In an infected cell,
dsRNA, probably produced both by the cell and by the virus,
activates PKR as the infection progresses from early to late
stage (30). Accumulation of the VAI RNA most likely pre-
cedes the accumulation of dsRNA, and upon accumulation,
VAI RNA binds to and prevents the activation of the kinase.
All of these events occur in a complex milieu in the context of
cellular translation apparatus. Indeed, it has been suggested
that the activation of the PKR (and perhaps the inhibition by
VAI RNA) may be localized events in that the messages are
selectively inhibited by PKR (41).In addition, there is evidence
that the VAI RNA binds to viral mRNAs in vitro (31). We
were therefore interested in determining whether the pheno-
type of the mutant VAI RNAs that we analyzed previously in
the context of virus could be reproduced in vitro with a
partially purified PKR preparation and whether a correlation
exists between the in vitro phenotype, the previously reported
in vivo studies (12, 15), and the structural alterations in these
mutant RNAs as a consequence of mutations. In this report,
we describe the properties of the mutant RNAs with regard to
their ability to block the activation of partially purified PKR in
vitro, present experimentally derived secondary structures of
the mutant RNAs, and show that there exists an excellent
correlation between the secondary structures and the inhibi-
tion of PKR by these mutants. It has been suggested that the
VAI RNA does not activate the PKR in virus-infected cells
because of mismatches in the imperfectly base-paired long
duplex regions (26, 41). We constructed VAI mutants in which
the two imperfectly base-paired long duplex regions were
converted to perfectly base-paired duplex regions and analyzed
in vitro. These mutants also failed to activate PKR in vitro.
Thus, it seems that the failure of VAI RNA to activate PKR
may not be the result of mismatches in the duplex regions, and
the function of the two long duplex regions of the VAI RNA
may be to hold the sequences of the central domain in a
conformation that is optimal for function.
MATERIALS AND METHODS
Cells, viruses, and plasmids. HeLa cells suspension cultures
were grown in S-MEM with 7% donor calf serum. Mutant VAI
RNA genes used in this study have been reported earlier (4, 5,
12). Substitution mutants sub7O7, sub7O9, sub741, sub743, and
sub745 through sub749 are linker-scan substitution mutants in
which HindTTT linker sequences are substituted in the following
locations: sub7O7, between nucleotides 18 and 27 (numbering
based on the G start site); sub7O9, between nucleotides 43 and
53; sub741, between nucleotides 76 and 90; sub743, between
nucleotides 90 and 105; sub745, between nucleotides 105 and
117; sub746, between nucleotides 116 and 126; sub747, be-
tween nucleotides 122 and 134; sub748, between nucleotides
134 and 143; and sub749, between nucleotides 140 and 150.
Mutant in708 is an insertion mutant in which a HindIII linker
sequence is inserted after nucleotide 27. Mutant VAI-CB was
constructed by substituting DNA sequences between Csp45I
(+61) and BstEll sites (+99) with a duplex oligonucleotide,
the sequence of which is 5'-CGAACCCCAACCCCGGT
CGTCCGCCATGATACCCATGCG-3'. VAI-BR was con-
structed by substituting DNA sequences between BstEII (+99)
and EcoRT (+ 160) sites with a duplex oligonucleotide with the
sequence 5'-GTTACCGCCCGCGTGTCGAACCCAGGTG
TGCGACACCAGACCACGGAAGAGTGCCCCTITTTT
TG-3'. Mutant VAI-CR was constructed by recombining ap-
propriate DNA fragments from VAI-CB and VAI-BR plas-
mids. Mutations in the VAI genes were confirmed by DNA
sequence analysis.
Purification of PKR. PKR was purified by the procedure of
Samuel and coworkers, with modifications (3, 48). The cyto-
plasmic extracts were prepared from HeLa suspension cultures
(10). The postnuclear fraction was centrifuged at 13,000 rpm in
a Sorvall RC5B SS34 rotor for 20 min at 4°C. The supernatant
(fraction T) was centrifuged at 100,000 x g for 2.5 h at 4°C to
pellet ribosomes. The ribosomal pellet was suspended in buffer
X (20 mM Tris-HCl [pH 8.0], 100 mM KCl, 5mM MgCl2, 5
mM 2-mercaptoethanol, 50,uM EDTA, 5% glycerol) contain-
ing 1 mM phenylmethylsulfonyl fluoride (PMSF), 1,ug of
leupeptin per ml, and 500 U of aprotinin per ml and homog-
enized in a Dounce homogenizer with 15 to 20 strokes.
Potassium chloride was then added to the homogenate to a
final concentration of 0.7 M, and the volume was adjusted with
buffer X to reach an optical density at 280 nm of 150 to 175
U/ml. The homogenate was kept on ice for 90 min and then
centrifuged at 100,000 x g for 5 h. The supernatant (fraction
TT) was subjected to 40 to 60% ammonium sulfate precipita-
tion. The precipitate obtained was dissolved in buffer Y (20
mM Tris-HCl [pH 8.0], 150 mM KCl, 1 mM EDTA, 5 mM
2-mercaptoethanol, 10% glycerol) containing 1 mM PMSF,
500 U of aprotinin per ml, and 1 ptg of leupeptin per ml and
dialyzed thoroughly against buffer Y containing 1 mM PMSF.
The dialysate (fraction III) was centrifuged at 14,000 rpm for
30 min at 4°C and passed through a DEAE-Sephacel column
(1.6 by 20 cm) equilibrated with buffer Y. The column was
washed with 2 column volumes of buffer Y, and flowthrough
and wash fractions were pooled and concentrated in an
Amicon ultrafiltration unit using a YM10 filter. The concen-
trate was dialyzed against Mono-S buffer (20 mM Tris-HCl
[pH 6.7], 50 mM KCl, 1 mM EDTA, 5 mM 2-mercaptoethanol,
10% glycerol, 1 mM PMSF). The dialyzed fraction (fraction
IV) was clarified by centrifugation at 16,000 rpm for 20 min at
4°C and then passed through a fast protein liquid chromatog-
raphy Mono-S column (HR10/30) equilibrated with Mono-S
buffer. The column was washed with 3 column volumes, and
the adsorbed proteins were eluted with a 0.05 to 1.0 M KCl
gradient in Mono-S buffer. The column fractions were ana-
lyzed for autophosphorylation activity. Fractions eluted be-
tween 0.4 and 0.5 M KCl containing PKR activity were pooled
and dialyzed against hexylamine-agarose (aminohexyl-agarose)
column buffer (HA buffer; 20 mM Tris-HCl [pH 7.5], 20 mM
KCl, 5 mM 2-mercaptoethanol, 5 mM MgCl2, 10% glycerol, 1
mM PMSF). The dialysate (fraction V) was centrifuged at
16,000 rpm for 20 min at 4°C and passed through a hexylamine-
agarose column (0.5 by 10 cm) equilibrated with HA buffer.
The column was washed with 3 column volumes with HA
buffer, adsorbed proteins were eluted with a salt gradient of
0.02 to 1.0 M KCl in HA buffer, and the fractions were assayed
for PKR activity. Fractions eluted at 40 to 150 mM KCl were
pooled and dialyzed against HA buffer, bovine serum albumin
was added to a final concentration of 100 ,ug/ml, and the
preparation was stored at -70°C until use.
Autophosphorylation of PKR. Autophosphorylation of PKR
was carried out in a 50-,u reaction mixture consisting of 10 [ul
of hexylamine-agarose column fraction, 20 mM Tris-HCl (pH
7.5), 2 mM 2-mercaptoethanol, 4 mM magnesium acetate, 10
,uCi of [-y-32P]ATP (specific activity, 30 Ci/mmol; NEN) and
concentrations of reovirus RNA as dsRNA with concentra-
tions indicated in the figure legends. The reaction mixture was
incubated at 30°C for 30 min, the reaction was terminated by
the addition of 50 ,ul of 2x SDS sample buffer (0.125 M
Tris-HCl [pH 6.8], 4% SDS, 20% glycerol, 10% 2-mercapto-
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FIG. 1. Experimentally derived secondary structure of the VAI RNA. (A) Secondary structure reported by us and others in which the sequences
of the central domain are presented as a short stem-loop (12, 38). (B and C) Two alternate secondary structures for the central domain reported
by Ma and Mathews (28) and by Pe'ery et al. (45), respectively. Data discussed in this report are based on the secondary structure model presented
in panel A. A to D are looped regions.
ethanol), the reaction mixture was boiled for 5 min, and
phosphorylated proteins were analyzed on SDS-12.5% poly-
acrylamide gels with prestained SDS molecular weight markers
(Sigma catalog no. SDS-7B) (12). Reovirus RNA was prepared
exactly as described previously (22) with the Dearing strain of
reovirus type 3. The viral RNA was further purified by passing
it through a Sephadex G-50 column. Without this step, the
RNA failed to activate PKR in vitro.
Preparation of WT and mutant VAI RNAs and PKR block
assays. The mutant VAI RNA genes were first transferred to
a plasmid containing a T7 promoter with appropriate recom-
binant DNA techniques (2, 27) and then transcribed in vitro,
using T7 RNA polymerase as described previously (12) with an
in vitro transcription kit (Riboprobe II core system; Promega
catalog no. P2590). The RNA samples were gel purified by
electrophoresis on a 6% native polyacrylamide gel before use.
To test the efficiency with which the mutant VAI RNAs
blocked the activation of PKR by dsRNA, the hexylamine-
agarose column fraction was preincubated at 30°C for 10 min
with in vitro-transcribed VAI RNA prior to the addition of
dsRNA and [-y-32P]ATP. The phosphorylated proteins were
analyzed on SDS-12.5% polyacrylamide gels (12).
Secondary structure analysis. In vitro-transcribed wild-type
(WT) and mutant VAI RNAs were 3' end labeled (12, 44) and
partially digested with single-strand-specific RNases Tl, U2,
and BC, such that the majority of the molecules were not
digested and rest of the molecules were cleaved only once (12).
The cleavage products were then resolved in 14% DNA-
sequencing gels (12).
RESULTS
The secondary structure of VAI RNA as determined by us
and others consists of two long duplex regions, stems I and III,
connected at the center by a short duplex region, stem II (Fig.
1A). Stem I consists of a duplex in which nucleotides 1 to 22
are base paired to nucleotides 134 to 155 (numbers here
represent the positions of the nucleotides from the 5' end with
a G start site [12]). Stem II consists of a short duplex in which
nucleotides 31 to 35 are base paired to nucleotides 128 to 132.
In stem III, the longest of these, nucleotides 37 to 62, are base
paired with nucleotides 71 to 94. As a result, nucleotides 63 to
71 exist as a loop (loop B). The most important part of the
molecule is the central part, referred to as the central domain,
the structure of which is complex and poorly defined. This part
of the molecule contains a small loop in the 5' side (loop A,
nucleotides 23 to 30) and a short stem-loop in the 3' side in
which nucleotides 95 to 129 fold such that nucleotides 99 to
102 pair with nucleotides 118 to 121. As a result, nucleotides
103 to 117 exist as a large loop (loop C). In this model,
nucleotides 94 to 99 and nucleotides 121 to 129 do not pair and
exist as single-stranded regions (nucleotides 121 to 129 repre-
sent a minor loop, loop D). Because there is very little base
pairing in this region, it has been difficult to determine the
precise secondary structure for this region. Two alternate
secondary structures have been proposed for this region by
Mathews and coworkers (Figs. 1B and C; references 28 and 45,
respectively); the structure shown in Fig. 1B is more recent
(28). Further mutational analysis of the central domain, as well
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FIG. 2. Locations of the insertion and linker-scan mu
secondary structure of the WT VAI RNA. Insertion mut.
by a triangle. Linker-scan mutations are boxed. Further d
mutants can be obtained from reference 12.
as determination of the three-dimensional struc
VAI RNA molecule, will be necessary to define t
for this region accurately. In this report, we discus
based on the secondary structure model propose
by us and others and shown in Fig. 1A. As discu
interpretation of our results will not be affected b
changes in structure for this region.
We previously constructed and characterized
adenovirus mutants in which the VAI gene was r
by deletion, insertion, and linker-scanning mutagei
These mutants were analyzed for growth yield,
synthesis, and in some cases for the phosphorylat
These and other results (38) led to the suggc
elements present in the central domain are crit
function of VAI RNA. Subsequently, several of th
were analyzed for binding with PKR in vivo and i
This study revealed that the functional domain a
binding domains are indistinguishable. In the prese
have analyzed 10 of these mutants in vitro wit}
purified PKR. The locations of these substitution
the secondary structure of VAI RNA are shown i
In vitro inhibition of partially purified PKR by
RNA. We purified PKR from cytoplasmic extracts prepared
from HeLa cell suspension cultures. Ribosomes were pelleted
from the cytoplasmic extracts and washed with 1.0 M ammo-
nium chloride, and the ribosome salt wash was fractionated by
ammonium sulfate fractionation and passage through DEAE-
Sephacel, Mono-S, and hexylamine-agarose columns as de-
tailed in Materials and Methods. At each stage, the PKR
activity was monitored in an autophosphorylation assay using
reovirus RNA as the activator. The PKR activity could be
detected only after the DEAE-Sephacel step, presumably
because of an inhibitor that copurifies with PKR until this step.
Figure 3A shows an SDS-polyacrylamide gel electrophoresis
(PAGE) analysis of selected fractions of the hexylamine-
agarose column stained with silver. The PKR activity of the
corresponding fractions is shown in Fig. 3B. It is clear that the
protein at the hexylamine-agarose column stage is considerably
purified, and fractions which show PKR activity contain not
more than five polypeptides (Fig. 3A). The position of the
sub745 phosphorylated polypeptide (Fig. 3B) coincides with the major
polypeptide at the 68-kDa position (Fig. 3A). Another band
that migrated at approximately the 50-kDa position could be a
degradation product of PKR (shown by an open triangle in Fig.
3A) (13). The active fractions from this column (abbreviated as
HA fractions hereafter) were pooled and used for the enzyme
activity assays described here. The PKR has been shown to
respond to dsRNA with a bell-shaped curve, activation of the
enzyme with a low concentration of dsRNA, and inhibition at
high concentrations (11, 20). To ensure that our enzyme
preparation shows this property and to determine the dsRNA
concentrations required for optimum activation, autophos-
phorylation was carried out with increasing concentrations of
dsRNA. The enzyme showed the activity profile typical of the
PKR, with activation between 0.02 to 0.2 ,ug/ml and inhibition
beginning at 2.0 ,ug/ml (Fig. 3C). This and other PKR prepa-
rations of similar quality were used in the VAI RNA-mediated
block assays reported here. Each PKR preparation was tested
for its response to dsRNA concentrations before use.
An aliquot of the pooled HA fractions was preincubated
itations in the with various concentrations of in vitro-transcribed, gel-purified
ation is shown WT VAI RNA for 30 min, and then dsRNA was added along
letails of these with [y-32P]ATP. The 32P-labeled protein was then analyzed by
SDS-PAGE. We also compared the PKR obtained from the
Mono-S column fractions in the inhibition assays using the WT
VAI RNA. With the HA fractions, activation of PKR was
cture of the completely inhibited at 500 ng of VAI RNA per ml. However,
-he structure we consistently observed that the Mono-S column fractions
;s our results required a 10-fold higher concentration of VAI RNA (5
d previously jig/ml) for complete inhibition (data not shown). This value is
assed below, comparable to that observed by other investigators (28, 45).
y any minor The reason for the difference in the sensitivity of the two
enzyme preparations for the VAI RNA is not clear. It is
a series of possible that the impurities present in the Mono-S enzyme
mutagenized preparations nonspecifically bind to VAI RNA and reduce its
nesis (5, 12). effective concentrations. Alternatively, the Mono-S column
for protein fractions may contain factors that inhibit the autophosphory-
:ion of PKR. lation. This aspect was not investigated further.
est that the Phenotypically WT VAI mutants sub7O7, in708, and sub749
tical for the block the activation of the PKR efficiently in vitro. Mutants
iese mutants sub7O7 and in708 contain HindIII linker sequences substituted
in vitro (15). in the loop A region of the central domain, whereas sub749
nd the PKR contains mutations in the 3' side of stem I (Fig. 2). Earlier, we
=nt study, we showed that in the context of the viral chromosome, these
h a partially three mutants function efficiently. These mutants were tran-
mutants on scribed in vitro with T7 RNA polymerase and gel purified.
n Fig. 2. Various concentrations of these RNAs were then assayed in
the WT VAI vitro for the inhibition of PKR derived from the HA fractions.
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FIG. 3. Purification and characterization of PKR from HeLa cells.
Ribosomes were pelleted, washed with potassium chloride, and then
fractionated by ammonium sulfate precipitation and passage through
DEAE-Sephacel, Mono-S, and hexylamine-agarose columns as de-
scribed in Materials and Methods. The column fractions were assayed
for PKR activity in an in vitro autophosphorylation assay with reovirus
RNA as the activator. The phosphorylated proteins were analyzed on
an SDS-12% polyacrylamide gel. (A) Silver stain of the SDS-polyacryl-
amide gel of the hexylamine-agarose column fractions. Active fractions
from the Mono-S column were pooled, concentrated, and applied to a
hexylamine-agarose column. The proteins in each fraction were frac-
tionated on an SDS-12% polyacrylamide gel with prestained molecu-
lar weight markers (not shown) and stained with silver (57). The
arrowhead indicates the polypeptide corresponding to PKR. The
triangle indicates a polypeptide that could be a result of proteolysis of
PKR (13). (B) Assay for PKR activity of the hexylamine-agarose
column fractions shown in panel A. An aliquot of the column fractions
was tested in an autophosphorylation assay. Lane C corresponds to
autophosphorylation assay of the Mono-S fraction in the absence of
reovirus RNA. The numbers at the top of panels A and B are fraction
numbers. Data for the other column fractions and positions of the
molecular weight markers are not shown. The arrowhead shows the
phosphorylated polypeptide. Reovirus RNA at a concentration of 100
ng/ml was used for activation. (C) Titration of PKR activity with
dsRNA. PKR was assayed in the presence of various concentrations of
reovirus (Reo) dsRNA.
Data from one such experiment are shown in Fig. 4. Each
mutant was assayed at least four times, and control experi-
ments with WT VAI RNA were always carried out in parallel.
Phosphorylation of PKR in each experiment was quantitated
by scanning the autoradiograms with a laser densitometer.
Average values with error bars for each mutant are shown in
Fig. 5. Mutants sub7O7, in708, and sub749 inhibited the PKR as
efficiently as did the WT. In all cases, significant inhibition was
observed at 0.1 ,ug/ml and the enzyme was inhibited completely
at 0.5 ,ug/ml.
In mutants sub7O7, in708, and sub749, the short stem-loop of
the central domain is intact. An important consequence of
mutations in an RNA molecule is the perturbations in their
secondary structures. Because the function of the VAI RNA
is dependent on the structure, it was important to determine
the structural changes that these RNAs may have undergone
as a result of nucleotide substitutions. The in vitro-tran-
scribed RNAs were labeled at their 3' ends with [32P]pCp (44)
and subjected to low concentrations of single-strand-specific
RNase T, (cleaves after G), U2 (cleaves after A), or BC(cleaves after pyrimidines), such that the majority of the
molecules were not cleaved and the remainder of the mole-
cules cleaved only once (12, 38). The cleavage products were
resolved on 14% DNA-sequencing gels along with a ladder
marker developed by subjecting the 3'-end-labeled RNA (the
same as the mutant) to limited alkaline hydrolysis. The RNA
sequences were folded by using a computer-assisted folding
program (21, 58) such that the unpaired bases identified in the
RNase sensitivity experiments were not allowed to base pair.
The derived secondary structures of the mutant RNAs and the
RNase cleavage sites in the RNAs for sub7O7, in708, and
sub749 are shown in Fig. 6. An important feature of all three
RNAs is that the central short stem-loop structure is intact and
all alterations are below stem II. Alterations of secondary
structures in sub7O7 and in708 reside in the loop A region. For
example, mutations in sub7O7 lead to enlargement of loop A
from its normal size of 8 nucleotides to 11 nucleotides. As a
result, nucleotides 132 to 136 also do not base pair. In addition,
the size of stem I is also somewhat shortened. In sub7O8, the
alterations are confined to loop A, the size of which is changed
from 8 nucleotides to 16 nucleotides. In sub749, unlike the WT,
the 5'- and the 3'-terminal sequences do not base pair and exist
as two large loops (Fig. 4). In summary, these results indicate
that any structural alterations below stem II do not affect the
ability of the RNAs to inhibit PKR in vitro.
sub7O9, sub741, sub743, and sub745 through sub748 do not
block autophosphorylation of PKR in vitro. Mutations in
sub7O9 and sub741 contain alterations in the 5' and 3' sides,
respectively, of the middle portion of the apical stem-loop
(stem III) (Fig. 2). These sequences are critical for the
maintenance of the apical stem-loop. In sub743, sub745,
sub746, and sub747, mutations reside in the short stem-loop of
the central domain. Mutant sub748 contains mutations in a
region that is proximal to the short stem-loop of the central
domain. As discussed below, all of these mutations are ex-
pected to destroy the central domain. Adenovirus mutants
which harbor these mutations were shown previously to be
defective (4, 12). These mutant RNAs were assayed for the
inhibition of PKR activity in vitro with HA fractions as
described above. sub7O9,sub741,sub743, and sub745 to sub747
showed little or no inhibition of kinase activity at 100 ng of
RNA per ml and only a modest inhibition at 200 ng/ml. More
than 80% inhibition was observed for the WT RNA at 100
ng/ml, and inhibition increased to 90% at 200 ng/ml. At 500
ng/ml, inhibition was complete. Thus, at low concentrations,
the mutants that failed to function in our virus experiments
failed to block the activation of PKR in vitro. As the RNA
concentrations increased to 500 ng/ml, some of the RNAs
showed a moderate inhibition (sub743, sub745, and sub746).
When the RNA concentration was increased to 1.6 ,ug/ml,
nearly total inhibition of kinase activity was observed for all of
the mutants except sub7O9 and sub741. These mutants required
much higher concentrations ofRNA for the inhibition. Results
for mutant sub748 are interesting. Although this RNA did not
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FIG. 4. In vitro inhibition of PKR activity by various VAI mutants. WT and mutant VAI genes were transcribed in vitro, purified on native
polyacrylamide gels, and assayed for inhibition of autophosphorylation of PKR derived from hexylamine-agarose column fractions with various
concentrations of VAI RNAs. The phosphorylated polypeptides were analyzed by SDS-PAGE as detailed in Materials and Methods. The
phosphorylated 68-kDa polypeptide is shown by an arrowhead. Reovirus (Reo) RNA at a concentration of 100 ng/ml was used for activation of
the enzyme. Lane C corresponds to the control experiments in which the autophosphorylation assay was carried out in the absence of VAI RNA.
significantly inhibit the kinase activity at a low concentration
(100 ng/ml), at 500 ng/ml it inhibited the enzyme activity
almost as well as the WT did. In summary, at low concentra-
tions of RNA, there is an excellent correlation between the in
vitro phenotype of these mutant RNAs and their previously
reported in vivo phenotype.
VAI mutants fail to block the activation of PKR in vitro
when the short stem-loop in the central domain is disrupted.
The secondary structures of the defective mutant VAI RNAs
were determined by RNase digestion followed by folding of the
RNA sequences as described above and shown in Fig. 6.
Although all of these mutants contain 8- to 10-nucleotide
substitutions, they affected the secondary structure rather
dramatically, and there was a large variation in their secondary
structures. The principal feature of these secondary structures
was the loss of the short stem-loop of the central domain. In
sub7O9, most of the sequences of the apical stem-loop exist as
a single-stranded region, whereas in sub741, these sequences
exist as multiple small loops. The nucleotide sequences that
are substituted in these mutants are critical for the mainte-
nance of the apical stem-loop (and also the central domain).
These two mutants are also interesting in one other respect:
they both fail to block PKR activity with RNA concentrations
as high as 1.6 ,ug/ml, whereas at these RNA concentrations, all
other defective mutants inhibit the activity of the enzyme
completely (Fig. 4). These results indicate that at very high
concentrations, the apical stem-loop alone may be able to
inhibit the enzyme activity.
In sub743, sub745, sub746, and sub747, mutations reside in
the short stem-loop region of the central domain (Fig. 2).
These mutants undergo different structural alterations depend-
ing on the location and the nature of the bases that are
substituted (Fig. 6). However, none of these mutants retain the
central short stem-loop structure of the central domain. It is
noteworthy that most of stem I and the apical stem-loop are
intact in these mutants.
The structural alterations in mutant sub745 are particularly
noteworthy. This RNA contains two smaller loops below stem
II, roughly in the same positions as those of the mutant sub7O7.
One of these loops (between nucleotides 22 and 37) also
resembles the loop between nucleotides 22 and 38 of sub7O8.
The short stem-loop of the central domain of the WT RNA
(Fig. 1B) somewhat resembles the large loop present in the 3'
side of sub745, between nucleotides 92 and 119. What is more
important is that the position and the size of the large loop in
the 3' side of sub745 have striking similarities to the large loop
present in the same location in the alternate WT structure
described by Ma and Mathews (28) (Fig. 1B). In both cases, the
size of this loop is about 26 bases. Thus, although the central
portion of sub745 RNA has features that in some respects
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FIG. 5. Bar diagrams showing the inhibition of PKR by WT and VAI mutant RNAs. The VAI genes were transcribed in vitro, gel purified, and
assayed in in vitro PKR autophosphorylation assays as detailed in Materials and Methods. Bands corresponding to the phosphorylated PKR from
the autoradiograms were quantitated by densitometer scanning. The experiments were repeated at least four times, and the average values and
error bars are shown. Values shown on they axis correspond to the percent activity of PKR remaining compared with control experiments in which
autophosphorylation was carried out without VAI RNA. Control values were taken as 100%.
resemble the central domain of the WT RNA, sub745 fails to
function in vivo as well as in vitro at low concentrations of
RNA. These results underscore the importance of the ele-
ments present in the short stem-loop of the central domain in
the function of the VAI RNA.
At 100-ng/ml concentrations, sub748 RNA can inhibit en-
zyme activity by about 25%, which is better than the value for
other defective mutants but still not close to that of WT RNA,
which shows more than 80% inhibition (Fig. 5). However, at
500-ng/ml concentrations, a nearly complete inhibition of
enzyme activity can be observed. This property is not reflected
in its structure. This RNA shows a much longer apical stem-
loop (Fig. 6). However, the folding of the sequences in the
other part of the molecule has little resemblance to the central
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FIG. 6. Experimentally derived secondary structures of various mutant VAI RNAs based on single-strand-specific RNase cleavage patterns.
RNase cleavages are shown by arrowheads. Pronounced cleavages are shown by solid circles next to the arrowheads. Weak cleavages are shown
by open circles next to the arrowheads. The mutated nucleotides are boxed. All VAI RNAs derived from T7 constructs contain six uridine residues
followed by a G rather than the one to four U residues found in vivo (12).
domain of the WT RNA. It is conceivable that at higher
concentrations of RNA, the extended apical stem-loop facili-
tates the inhibition process. Nonetheless, at low concentra-
tions, the in vitro phenotype of this RNA is in agreement with
its in vivo phenotype.
VAI RNA mutants in which the imperfectly base-paired
duplex region is changed to perfectly base-paired regions do
not activate PKR in vitro. We next examined the role of the
G-U pairs and mismatches in the imperfectly base-paired
duplex regions in the function of the VAI RNA. We consid-
ered this study important for two reasons. First, it has been
thought that the VAI RNA would not activate the kinase
because of the mismatches and G-U pairs in the long duplex
regions (26, 41), although one study did show that the WT VAI
RNA can activate PKR in vitro (14). Each of the two long
duplex regions (stems I and III) contain five G-U base pairs
and two mismatches (Fig. 7). In addition, stem III also contains
two stacked bases (nucleotides 42 and 43). Second, we wanted
to determine whether these mismatches have any role in
blocking the activation of PKR. While the precise mechanism
by which VAI RNA functions is not clear, recent evidence
suggests that it would bind to PKR in the same region as that
of dsRNA and somehow interfere in the dsRNA-mediated
activation (16, 24, 36, 43).
To determine whether the imperfectly base-paired long
dsRNA segments of the VAI RNA have any biological role, we
constructed three VAI RNA mutants. The first mutant, VAI-
CB, was constructed by replacing the DNA segment from
Csp45T (+61) and BstEll (+99) sites with a chemically synthe-
sized double-stranded oligonucleotide with appropriate nucle-
otide sequence changes (Fig. 7). Two bases were added to stem
III between residues 91 and 92 such that these two bases would
pair with the two stacked bases, A and U at 41 and 42,
respectively. Changing the U residue at 94 (or 92 of the WT
numbering) generates a pentanucleotide sequence, ACCCA
(boxed in Fig. 7), that is also present between nucleotides 120
and 126 (or 118 and 124 based on WT numbering). This
sequence is conserved in the VAI genes of different serotypes
(28). When this gene is transcribed, it should produce an RNA
with a perfectly base-paired apical stem-loop. The second
mutant, VAI-BR, was constructed by replacing the DNA
sequences of the VAI RNA gene between BstEII and EcoRI
(+ 161) sites with a chemically synthesized double-stranded
oligonucleotide with appropriate base changes. RNA tran-
scribed by this gene would contain perfectly base-paired stem
T. The last mutant, VAI-CR, is a combination of VAI-CB and
VAI-BR and contains perfectly base-paired stems I and TTT.
These mutants were first tested for their ability to activate
PKR in vitro with HA fractions. The in vitro phosphorylation
assays were carried out by replacing reovirus RNA with various
concentrations of the above-described mutant VAI RNAs; the
radiolabeled polypeptides were analyzed by SDS-PAGE. Con-
trol autophosphorylation assays with various concentrations of
reovirus RNA were also carried out in a parallel fashion.
Despite repeated efforts, we did not detect the activation of the
PKR with WT VAI RNA or with the three mutants, VAI-CB,
VAI-BR, and VAI-CR. As expected, only reovirus RNA
activated PKR in vitro (data not shown). We conclude that the
long duplex regions of VAI RNA are not capable of activating
PKR even when the mismatches in the duplex regions are
converted to perfectly base-paired regions.
Mutants VAI-CB, VAI-BR, and VAI CR can block activation
of PKR in vitro as efficiently as or better than the WT VAI
RNA. To determine whether these mutant RNAs are capable
of blocking the activation of the kinase with the same efficiency
as the WT VAI RNA molecule, the mutant genes were
transcribed in vitro, and the RNAs were purified and then
assayed for inhibition of the autophosphorylation of PKR with
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FIG. 7. Details of restriction endonuclease sites, G-U pairs, mismatches, and stacked bases in the WT VAI RNA sequences and the
single-strand-specific RNase cleavage map of the WT, VAI-CB, and VAI-BR RNAs. As no structural change is observed, the cleavage maps are
shown on the WT structure. Arrowheads indicate RNase cleavages. Pronounced cleavages are shown by solid circles next to the arrowheads. Weak
cleavages are shown by open circles next to the arrowheads. Csp45I, BstEII, and EcoRI sites that are used for constructing the three mutants are
shown on the WT RNA sequence. The conserved sequence ACCCA found in the VAI RNAs of many serotypes and the additional copy ofACCCA
in stem III of VAI-CB are boxed. The G-U pairs are shown by asterisks. Mismatches are shown by arrows. Two stacked bases are shown by plus
sign. In VAI-CB, two bases that are inserted to pair with two stacked bases at 41 and 42 are shown by diamonds. The cleavage map of VAI-CR
is not shown.
HA fractions (Fig. 8). Average values obtained for these
mutants from three independent experiments with error bars
are shown in Fig. 9. Mutant VAI-CB inhibited the PKR as
efficiently as the WT VAI RNA did; at an RNA concentration
of 100 ng/ml, the VAI-CB inhibited the PKR more than 80%,
which is comparable to the value for the WT VAI. Interest-
ingly, the VAI-BR and VAI-CR RNAs were more active than
the WT RNA. VAI-BR inhibited the kinase activity two- to
threefold more efficiently than the WT RNA. VAI-CR was
even more active than VAI-BR. At an RNA concentration of
40 ng/ml, VAI-CR inhibited PKR almost completely, whereas
only about 50% inhibition was observed for the WT and
VAI-CB RNAs. These results suggest that the perfect base
pairing of the duplex regions promotes the inhibitory proper-
ties of the VAI RNAs.
Central domain in VAI-CB, VAI-BR, and VAI-CR is intact.
Our strategy to construct the VAI mutants with perfectly
base-paired duplex regions involved multiple-base substitu-
tions (Fig. 7). This may perturb the native secondary structures
of the VAI RNAs. Because the ability of the VAI RNA to
block the kinase is strictly dependent on the secondary struc-
tures of the RNAs, we determined the secondary structures of
these three RNAs as described above. The single-strand-
specific RNase cleavage pattern of the RNAs is shown in Fig.
10, and the cleavage map is shown in Fig. 7. Overall, the
cleavage pattern of these three RNAs is comparable to that of
the WT RNA, indicating that there is no change in the
structures of these RNAs. There are a few minor differences,
however. In VAI-BR, in which stem is a perfect duplex
structure, the nucleotides in the central domain are less
susceptible to RNase attack. For example, the cleavages that
are found in WT RNA at nucleotides 131, 136, and 138 are not
detected. In addition, a number of strong cleavages in the short
stem-loop that are characteristic of the WT RNA are changed
to weak cleavages or are absent. In VAI-CB, in which the
apical stem-loop is a perfect duplex structure, the loop, (loop
B) is not cleaved efficiently. Loop A also appears to be less
susceptible to RNases. As expected, in VAI-CR, in which both
long duplex regions are made of perfect base pairs, the
mutational effects of VAI-CB and VAI-BR are combined. In
this RNA, most of the cleavages in the central domain are
weak and the majority of the cleavages found in stem I and
loop B of the WT RNA are absent (Fig. 10). The cleavage map
of VAI-CR, which is a combination of VAI-CB and VAI-BR,
is not shown. Thus, it seems that when the VAI RNA contains
perfectly base-paired stems, the molecule is more compact and
the single-stranded regions are probably less exposed. This
may also have some effect on the tertiary structures of these
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FIG. 8. In vitro inhibition of PKR activity by VAI-CB, VAI-BR,
and VAI-CR. WT and mutant VAI genes were transcribed in vitro,
purified on native polyacrylamide gels, and assayed for inhibition of
autophosphorylation of PKR derived from hexylamine-agarose col-
umn fractions with various concentrations of the VAI RNAs. The
phosphorylated polypeptides were analyzed by SDS-PAGE. The phos-
phorylated 68-kDa polypeptide is shown by an arrow. Sample C
corresponds to PKR activity in the absence of VAI RNA. Reo,
reovirus.
RNAs. These results also suggest that the central domain
probably is more stable in VAI-BR and VAI CR mutants. This
may explain why these mutants are more efficient in blocking
PKR activation.
DISCUSSION
By using whole cells and a series of adenovirus mutants, we
recently showed that the critical elements required for function
of the VAI RNA are located in the central domain (12) and
that these same elements bind to PKR and inactivate it (15).
The purpose of this investigation was twofold: (i) to determine
whether the correlation that was made previously between
binding and function (12, 15) can be extended to the in vitro
phenotype of these mutants, and (ii) to determine whether
mismatches in the duplex regions are responsible for the lack
of activation of PKR by the VAI RNA. The first question is
important because VAI RNA-mediated downregulation of
ribosome-bound PKR occurs in a complex milieu in which
multiple components of the cellular translation apparatus
interact. If the in vivo results can be reproduced in vitro with a
purified enzyme, it is reasonable to conclude that the preven-
tion of the activation of PKR by VAI RNA may be explained
by a simple RNA-protein interaction. Further, if a correlation
can be found between in vitro and in vivo phenotypes of the
mutants, it would be possible to further study the structure-
function correlations of the VAI RNA by introducing addi-
tional mutations into the RNA and by rapidly analyzing the
mutants in vitro with purified PKR. We repeatedly failed to
obtain sufficient quantities of homogeneous PKR protein. We
found that when the protein was purified to homogeneity, it
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FIG. 9. Bar diagram showing the inhibition of PKR by WT, VAI-
CB, VA-BR, and VAI-CR RNAs. The VAI genes were transcribed in
vitro, gel purified, and assayed in in vitro PKR autophosphorylation
assays as detailed in Materials and Methods. Bands corresponding to
the phosphorylated PKR from the autoradiograms were quantitated by
densitometer scanning. The experiments were repeated at least four
times, and the average values and error bars are shown. Values shown
on the y axis correspond to the percent activity of PKR remaining
compared with control experiments in which autophosphorylation was
carried out without VAI RNA. Control values were taken as 100%.
was very unstable. Inhibition assays with such an enzyme
preparation were not reproducible. Therefore, all assays were
carried out with hexylamine-agarose column-purified fractions.
The enzyme at this stage contains only about four to five
additional polypeptides. We believe that VAI RNA does not
require other viral or cellular components for the inhibition of
PKR. Although it is possible that the additional proteins
present in the PKR preparation influence the binding of VAI
RNA to PKR and subsequent inhibition of its activity, we
believe that is unlikely. While the PKR band was a major band
in all of our preparations, other proteins were not always
copurified or not copurified to the same extent. However, the
concentrations of the reovirus RNA required for the activation
of the enzyme as well as the concentration of VAI RNA
required for the inhibition of the enzyme activity remained
unchanged regardless of other polypeptides present in differ-
ent PKR preparations. Recent reports that VAI RNA can bind
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FIG. 10. Single-strand-specific RNase cleavage analysis of the WT
VAI, VAI-CB, VAI-BR, and VAI-CR RNAs. In vitro-synthesized
RNAs were labeled at the 3' ends (as described in Materials and
Methods) and digested with the indicated RNases, T,, BC, and U2.
The products were resolved in 14% DNA-sequencing gels. NE, no
RNase; M, ladders generated by partial digestion of the labeled RNA
under alkaline conditions (12). Cleavages specific to loops and the
short stem-loop of the central domain are bracketed. Sizes are
indicated in nucleotides.
to the PKR synthesized in bacteria or in reticulocyte lysates
support this conclusion (16, 24, 43).
When lower concentrations of VAI RNA are used in in vitro
assays, the inhibitory properties of VAI RNA mutants corre-
late remarkably well with their in vivo phenotype and the
structural integrity of the central domain. However, at high
concentrations of RNA, all mutants which contain the long
duplex regions can block the PKR activation even though the
central domain of these mutants is destroyed, suggesting that
this inhibition is nonspecific. These and our previously pub-
lished VAI RNA binding studies underscore the importance of
the central domain in the function of VAI RNA. Pe'ery et al.
(45) recently reported a similar study in which a number of
central-domain mutants were assayed for the inhibition of
PKR in vitro and also for the translational enhancement of a
reporter gene in cotransfection assays (53). Some of the
mutants failed to function in vivo in transient assays although
these mutant RNAs were able to block the PKR activity
efficiently in vitro, suggesting that the in vitro inhibition of
PKR may not correlate with the in vivo phenotype. At present,
direct comparison of our results with their results is difficult.
Not only are the mutants used in these two studies different,
but there are a number of protocol differences as well (e.g., the
preparation of VAI RNA, purity of PKR, in vitro autophos-
phorylation assays, and assays to determine the biological
activity of the mutant VAI RNAs). Perhaps the most impor-
tant discrepancy lies in the concentration of VAI RNA re-
quired for the complete inhibition of PKR activity in vitro. We
consistently have found that at RNA concentrations of 0.4
,ug/ml or less, PKR activity is inhibited completely. In contrast,
in studies reported by others (45), RNA concentrations of
about 5 ,ug/ml were required for the complete inhibition of
PKR in vitro. One explanation for the discrepancy is that the
PKR that we used in these studies is considerably more
purified than that used by others and thus requires less RNA
for inhibition (45). It is interesting that when we use a less
purified enzyme preparation (Mono-S column-purified frac-
tions), we require about 5,ug of VAI RNA per ml for complete
inhibition of the activity. A crude estimation indicates that in
our in vitro assays, the ratio of PKR to VAI RNA may be about
1:5. Currently we do not know the number of PKR molecules
per cell, and therefore comparison of the in vitro values with in
vivo values will not be feasible. Another explanation for the
discrepancy between our results and those of Pe'ery et al. (45)
may be due to the differences in the type of in vivo assays used
for the determination of the biological activity of the mutants.
Our mutants have been characterized in the context of virus
chromosome (4, 12), whereas the mutants used by Pe'ery et al.
were assayed for the translational enhancement of a reporter
gene in transient assays (53). VAI RNA has been shown to
stabilize mRNAs in transient assays (54). Therefore, compar-
ison of the in vitro phenotype of the mutants with in vivo
results obtained in such assays may not be very accurate.
Interestingly, we have observed that at high RNA concentra-
tions, all mutants except sub7O9 and sub741 inhibited the PKR
activity completely. All of these mutants except sub7O9 and
sub741 retain the apical stem-loop. Several explanations are
possible for this observation. For example, although long
duplex regions of VAI RNA cannot activate the kinase, at high
concentrations these duplex regions are capable of binding to
the enzyme and thus preventing the binding of dsRNA. Under
certain assay conditions, the apical stem-loop has been shown
to bind to PKR in vitro (37). Alternatively, the primary contact
site for PKR on VAI RNA is the short stem-loop of the central
domain, and the apical stem-loop makes a weak contact with
PKR. At high concentrations, when the short stem-loop of the
central domain is absent, the apical stem-loop is capable of
interacting with PKR and inhibiting the activity. A third
possibility is that PKR binds to the apical stem-loop at a site
independent of the binding sites of dsRNA and the short
stem-loop of the central domain. Binding of the apical stem-
loop to this site may somehow affect the activity of the enzyme.
There is a striking correlation between the in vitro inhibition
of PKR by VAI mutants and the maintenance of the secondary
structure of the central domain of the mutants. As stated
above, there are two principal components in this central
domain. One is a loop in the 5' side, and the other is a short
stem-loop in the 3' side. Recent mutational analysis has cast
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some doubt on the existence of this short stem-loop. It has
been suggested that these sequences may exist as a large loop
(28). The structure of the VAI-CB throws some light on this
issue. In the revised RNA structure, the conserved sequence
ACCC (nucleotides to 119 to 122) has been shown to base pair
with GGGU (nucleotides 37 to 40) (28). The mutant VAI-CB
contains two copies of this sequence, one between 92 and 97
and the second between 120 and 125. Because the sequences
between 92 and 97 are contiguous with the rest of the base-
paired RNA sequences of the apical stem, it is very likely that
the sequence GGGU (nucleotides 37 to 40) would pair with
the sequence ACCC located between 92 and 97 rather than
that present between 120 and 125. Therefore, at least in this
case, the original secondary structure is consistent with the
structure of the mutant. Whether it is a short stem-loop or a
large loop in the central domain, our in vitro block assays and
the secondary structure analysis suggest that it is this structure
that is critical for the function of the VAI RNA. The PKR must
recognize a precise structure in this region of the molecule. For
example, in mutant sub749, the structure of stem I is disrupted,
whereas in mutants sub7O7 and in708, the size of the loop in
the 5' side (loop A) is enlarged by 5 and 10 bases, respectively.
Nonetheless, the mutants are able to block the activation of the
kinase as efficiently as the WT because the short-stem loop of
the central domain is intact. Similarly, the apical stem-loop by
itself also may not play an important role in the downregula-
tion of the kinase activity. Several observations support this
argument. First, several deletion mutants with large trunca-
tions of the apical stem-loop retain full biologic activity as long
as the central short stem-loop is preserved in these mutants (4,
12, 38, 39). Second, mutants with WT apical stem-loop or
extended apical stem-loop but without the central short stem-
loop (sub743, sub745, sub746, sub747, and sub748) cannot
function in vivo or in vitro. Third, we have shown that the
binding of PKR to VAI RNA correlates with function, and
binding requires the elements present in the central domain of
the molecule; no binding or negligible binding of PKR was
observed when the apical stem-loop alone was present in the
molecule (15). Finally, VAII RNA and small RNAs of other
viruses do not complement the VAI RNA efficiently in vivo (5,
6) or block PKR activation in vitro as efficiently as VAI RNA,
even though these RNAs contain long duplex regions (8, 9,
15a, 17, 18). Thus, the role of the duplex regions such as stems
I, II, and III may be to maintain the nucleotide sequences in
the short stem-loop in a conformation that is optimal for
function. Any large mutations in stem I or stem III in a region
proximal to the central domain lead to dramatically altered
secondary structures of the central domain and result in the
loss of function. Other mutational analyses of the apical
stem-loop are also consistent with this suggestion (37).
Recent mutational analysis of PKR indicates that both
dsRNA and VAI RNA bind to the N-terminal 171-amino-acid
region (16, 24, 36, 43). This region, which is rich in basic amino
acid residues contains two functionally nonequivalent motifs,
one from residues 11 to 77 and the other from residues 101 to
167. The amino acid sequences of these two motifs display
regions of homology with each other and also with sequences
of other RNA-binding proteins (16) and may exist as alpha-
helical structures. It has been hypothesized that both of these
motifs make contacts with the activator, the dsRNA. A unique
property of the PKR is that the enzyme is activated and
inhibited by the RNA ligands: activation by dsRNA and
inhibition by VAI RNA. It has been shown that mutations in
PKR that fail to bind to dsRNA also fail to bind to VAI RNA
in vitro, suggesting that both dsRNA and VAI RNA bind to
the same regions in PKR. We previously showed that PKR
binds to the central domain of VAI RNA; most or all of the
apical stem-loop probably is not involved in binding (15).
Therefore, in this case, the N-terminal region of PKR must
recognize the short stem-loop (or a large loop based on the
revised secondary structure [28]) of the VAI RNA, and this
interaction must prevent the binding of the activator to the
enzyme. Thus, the N-terminal RNA binding domain of PKR
may display considerable flexibility in its interaction with these
two types of RNA ligands, a short stem-loop in the case of VAI
RNA and a perfectly base-paired duplex in the case of dsRNA;
these two interactions lead to opposing consequences. This
also indicates that the interactions of PKR with dsRNA and
VAI RNA must be different in nature. Although preliminary
mutational analysis of the N-terminal region of PKR indicated
that both types of RNAs bind to this region, a fine mutational
analysis in which each residue in the critical RNA binding
region is mutated will be required to resolve this issue. A
simple explanation is that VAI RNA, upon binding to PKR,
may induce a conformational change in the protein molecule
such that it cannot bind to dsRNA. There is precedence for
this. For example, the human immunodeficiency virus Tat
protein has been shown to change its structure upon binding to
TAR RNA (7, 42). Also relevant here are the tertiary interac-
tions that may influence the VAI RNA-PKR binding. Most
RNAs exist as globular structures in solution. It is therefore
certain that the tertiary structure of VAI RNA plays a very
important role in its binding to PKR. Our current knowledge
of the structure of VAI RNA does not allow us to make
predictions regarding the tertiary interactions. Control of gene
expression by RNA-protein interactions is a field that is rapidly
evolving. A number of RNA-protein interactions that modu-
late the activity of the proteins have been described recently
(reviewed in references 25, 34, 35, and 46). These studies
suggest that different proteins may employ fundamentally
distinct strategies to accomplish sequence-specific RNA bind-
ing. The modulation of PKR activity by two different types of
RNA ligands cannot be easily explained by using the previously
described models of gene regulation based on RNA-protein
interaction.
In this study, we have also evaluated the functional signifi-
cance, if any, of the mismatches in the long duplex regions of
VAI RNA. An earlier report suggested that at low concentra-
tions, VAI RNA can activate PKR in vitro (14). This is an
attractive hypothesis, for at early times, when the concentra-
tion of VAI RNA is very low, PKR could be activated,
resulting in a general inhibition of translation. At late times,
when VAI RNA accumulates to very high concentrations,
selectively, the inhibition of translation of viral mRNA would
be relieved. As a result, viral mRNA would be translated more
efficiently. Such an effect would contribute to the host shutoff
and promote viral replication. Despite repeated efforts, we
were unable to detect any activation of PKR in the presence of
VAI RNA. We considered it possible that failure of VAI RNA
to activate PKR in vitro resulted from mismatches in the
base-paired regions. For example, it has been shown that even
with a single mismatch, the dsRNA would not activate PKR
(40). The mutants with stem I or TII, with all of the mismatched
sequences corrected from Watson-Crick-type base pairs, did
not activate PKR in vitro. Similarly, VAI CR, in which both
stems I and III are perfect duplexes, also did not activate PKR
in vitro. These results are consistent with the observation that
the minimal length of the dsRNA required for the activation of
PKR is about 30 bp (29). The longest duplex region in these
mutants consists of 26 bp. The efficient inhibition of the
activation of PKR by these mutants also suggests that the bases
that are mutated do not play a significant role in the inhibition
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process per se. We also found reproducibly that when the
mismatches in stem I are corrected, the RNA can block the
activation of PKR more efficiently than the WT or the mutant
in which mismatches in stem III are corrected. This is most
likely because the perfectly base-paired stems stabilize the
structure of the central domain, which can bind to PKR more
efficiently than the WT or VAI BR, resulting in a more efficient
downregulation of PKR activity. Secondary structure analysis
of these RNAs supports this conclusion. The loops and the
single-stranded regions of the central domain in these RNAs
are, in general, less susceptible to cleavage by single-strand-
specific RNases (Fig. 7 and 10). Thus, the role of the long
duplex regions of the VAI RNA most likely is to maintain
sequences in the central domain in a conformation that is
optimal for the binding to and the inhibition of PKR.
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